Form 4: Bio-Rad Executive Reports RSU Vesting, Stock Transactions

Bio-Rad Laboratories EVP James Barry reported the vesting of 602 restricted stock units and the subsequent disposition of 217 shares for tax purposes.

Summary

• EVP, President, LSG James Barry of Bio-Rad Laboratories, Inc. reported transactions on September 1, 2025.
• Acquired 602 shares of Bio-Rad Class A Common Stock upon the vesting of restricted stock units (RSUs).
• Disposed of 217 shares of Bio-Rad Class A Common Stock at a price of $297.88 per share, likely to cover tax liabilities associated with the RSU vesting.
• Following these transactions, Barry directly beneficially owns 531.555 shares of Bio-Rad Class A Common Stock.
• The 602 vested RSUs comprised 178 units from a September 1, 2021 grant, 174 units from a September 1, 2022 grant, and 250 units from a September 1, 2023 grant.
• Remaining unvested RSUs from the September 1, 2022 grant are 174 units, and from the September 1, 2023 grant are 502 units.

Sentiment

Score: 5

Explanation: The filing is a neutral, routine disclosure of executive compensation vesting and tax-related stock disposition, with no inherently positive or negative implications for the company's operational or financial performance.

Positives

• The vesting of restricted stock units indicates the executive's continued long-term incentive compensation and alignment with shareholder interests.
• The acquisition of shares through vesting increases the executive's direct ownership in the company.

Negatives

• The disposition of 217 shares, while common for tax withholding, represents a reduction in the executive's direct shareholding.

Future Outlook

The filing indicates future vesting events for remaining restricted stock units from the 2022 and 2023 grants, with 174 units from the 2022 grant and 502 units from the 2023 grant still unvested.

Industry Context

This filing is a routine disclosure of executive stock transactions, common across all industries for publicly traded companies, and does not provide specific industry-wide insights.

Related Party Transactions

• James Barry, an executive of Bio-Rad Laboratories, acquired shares through the vesting of restricted stock units and disposed of shares for tax purposes, which are transactions between an insider and the company.

Stakeholder Impact

• Shareholders: Provides transparency regarding executive compensation and stock ownership, which is generally positive for corporate governance. The disposition of shares for tax purposes is a routine event and unlikely to significantly impact shareholder value.
• Employees: No direct impact on general employees.
• Management: Reflects the ongoing compensation structure for executives, aligning their interests with company performance through equity awards.

Next Steps

• Future tranches of the 2022 restricted stock unit grant (174 units remaining) are expected to vest annually.
• Future tranches of the 2023 restricted stock unit grant (502 units remaining) are expected to vest annually.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation transactions, specifically the vesting of restricted stock units and subsequent tax-related share dispositions. Such events are pre-scheduled and do not typically indicate a change in the company's fundamental outlook or performance. Therefore, it does not provide a basis for altering an existing investment thesis, leading to a 'hold' recommendation.

Keywords

Bio-Rad Laboratories, BIO, BIO.B, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Executive Compensation, Stock Transactions, James Barry